Infalible,Paris,Maquillaje,,de,L#39;Oréal,Belleza , Maquillaje , Cara , Bases,Base,$8,Duración,/ascension1852245.html, Infalible,Paris,Maquillaje,,de,L#39;Oréal,Belleza , Maquillaje , Cara , Bases,Base,$8,Duración,/ascension1852245.html, L#39;Oréal Paris Infalible Base Maquillaje Philadelphia Mall de Duración $8 L#39;Oréal Paris Infalible Base de Maquillaje, Duración Belleza Maquillaje Cara Bases L#39;Oréal Paris Infalible Base Maquillaje Philadelphia Mall de Duración $8 L#39;Oréal Paris Infalible Base de Maquillaje, Duración Belleza Maquillaje Cara Bases

L#39;Oréal Paris Free Shipping Cheap Bargain Gift Infalible Base Maquillaje Philadelphia Mall de Duración

L#39;Oréal Paris Infalible Base de Maquillaje, Duración


L#39;Oréal Paris Infalible Base de Maquillaje, Duración

Color:235 Miel  |  Tamaño:30 ml (Paquete de 1)

Descripción del producto

Infaillible, la base de larga duración 24 h y cero compromisos:
- Sin imperfecciones.
- No se emborrona.
- Sin efecto brillante.
- No piel seca.
- Sin efecto máscara.
Una fórmula con pigmentos de fijación extrema y ácido hialurónico, diseñada para permitir 24 horas de estanque* y comodidad. Resiste cualquier desafío con la tecnología Co-Resistium, que permite obtener una cobertura duradera minimizando los signos de fatiga. Al aplicar los pigmentos, incorporados en una red de polímeros adhesivos, forman una base resistente al sudor, que contrasta el exceso de sebo durando todo el día sin secar la piel. El tono de la piel se mantiene uniforme durante mucho tiempo. * Prueba de autoevaluación – 57 mujeres.


Aplicar de manera uniforme en la cara desde el centro y difuminando hacia el exterior. Se puede aplicar con los dedos, un cepillo o una esponja.

L#39;Oréal Paris Infalible Base de Maquillaje, Duración

This website is intended for UK healthcare professionals only Log in | Register

November 2021 Br J Cardiol 2021;28:155–62 doi: 10.5837/bjc.2021.051

Transcatheter mitral valve intervention

Rea Ganatra, Robert Smith


Mitral regurgitation is a common valvular heart disorder increasing with age. Many patients are ineligible for mitral valve surgery due to their age and other comorbidities. Left untreated, patients develop severe disease with a poor prognosis. The development of lower risk percutaneous mitral valve interventions has helped meet the needs of this previously untreated patient group. This review explores the recent and more established developments that have expanded the armamentarium for transcatheter mitral valve intervention.

| Full text

November 2021 Br J Cardiol 2021;28:134–38 doi: 10.5837/bjc.2021.048

Real-world evaluation of follow-up strategies after ICD therapies in patients with VT (REFINE-VT)

Patrick Tran, Leeann Marshall, Ian Patchett, Handi Salim, Shamil Yusuf, Sandeep Panikker, Michael Kuehl, Faizel Osman, Prithwish Banerjee, Harpal Randeva, Tarvinder Dhanjal


Implantable cardiac defibrillators (ICDs) can prevent sudden cardiac death, but the risk of recurrent ventricular arrhythmia (VA) and ICD shocks persist. Strategies to minimise such risks include medication optimisation, device programming and ventricular tachycardia (VT) ablation. Whether the choice of these interventions at follow-up are influenced by factors such as the type of arrhythmia or ICD therapy remains unclear. To investigate this, we evaluated ICD follow-up strategies in a real-world population with primary and secondary prevention ICDs.

REFINE-VT (Real-world Evaluation of Follow-up strategies after Implantable cardiac-defibrillator therapies in patients with Ventricular Tachycardia) is an observational study of 514 ICD recipients recruited between 2018 and 2019. We found that 77 patients (15%) suffered significant VA and/or ICD therapies, of whom 26% experienced a second event; 31% received no intervention. We observed an inconsistent approach to the choice of strategies across different types of arrhythmias and ICD therapies. Odds of intervening were significantly higher if ICD shock was detected compared with anti-tachycardia pacing (odds ratio [OR] 8.4, 95% confidence interval [CI] 1.7 to 39.6, p=0.007). Even in patients with two events, the rate of escalation of anti-arrhythmics or referral for VT ablation were as low as patients with single events.

This is the first contemporary study evaluating how strategies that reduce the risk of recurrent ICD events are executed in a real-world population. Significant inconsistencies in the choice of interventions exist, supporting the need for a multi-disciplinary approach to provide evidence-based care to this population.

| Full text

November 2021 Br J Cardiol 2021;28:144–7 doi: 10.5837/bjc.2021.049

Statin prescription and CV risk assessment in adult psychiatric outpatients with intellectual disability

Jamie Sin Ying Ho, George Collins, Vikram Rohra, Laura Korb, Bhathika Perera


We performed a single-centre study to assess the risk of cardiovascular disease (CVD) in psychiatry outpatients with intellectual disability (ID) using the QRISK-3 score.

There were 143 patients known to the ID psychiatry clinic enrolled. Of these, 28 (19.6%) had elevated CVD risk – defined as 10-year risk of heart attack or stroke of ≥10%. Of these, 57.1% were not prescribed statin therapy, which – after lifestyle measures – is recommended by National Institute for Health and Care Excellence (NICE) guidelines. The mean QRISK-3 score was 6.31% (95% confidence interval [CI] 4.84 to 7.78), with a relative risk of 3.50 (95%CI 2.34 to 4.67) compared with matched controls.

The high CVD risk identified in this study supports routine CVD risk assessment and management in adult outpatients with ID. Appropriate lifestyle measures and statin therapy could help reduce the excess CVD-related morbidity and mortality in ID patients.

| Full text

November 2021 Br J Cardiol 2021;28:148–52 doi: 10.5837/bjc.2021.050

Piloting structured focused TTE in outpatients during the COVID-19 pandemic: ‘old habits die hard’

Kay Dowling, Amanda Colling, Harriet Walters, Badrinathan Chandrasekaran, Helen Rimington


Transthoracic echocardiography presents a risk of COVID-19 transmission between an echocardiographer and the patient. Reducing the scanning time is likely to mitigate this risk for them both. British Society of Echocardiography (BSE) level 1 echocardiography offers a potential framework for focused scanning in an outpatient setting. There were 116 outpatients scheduled for a level 1 scan supplemented with additional pre-defined views, if required. Unexpectedly, a fifth of the scans were performed as an unintended full scan for a variety of reasons. Our results showed that focused scans were performed more quickly than full scans and below the NHS Test and Trace exposure cut-off of 15 minutes. However, if more than three sets of additional measurements were required then a full scan could be performed more quickly. Seniority of the echocardiographer and scan time had an inverse relationship. By examining the patients’ clinical records we were confident that all of the scans, whether focused or full, had answered the requestor’s clinical question. Although the COVID-19 vaccination programme should reduce the necessity of minimising exposure time during a scan there could still be a role for level 1 scanning during the COVID-19 recovery programme to tackle the vast lists of patients waiting for an echocardiogram.

| Full text

October 2021 Br J Cardiol 2021;28:139–43 doi: 10.5837/bjc.2021.042

Quality of life among people with atrial fibrillation with and without diabetes: a comparison study

Angela Hall, Andrew Robert John Mitchell, Lisa Ashmore, Carol Holland


Quality of life (QoL) is an essential consideration when managing the wellbeing of patients and assists in interpretation of symptoms, functional status and perceptions. Atrial fibrillation (AF) and diabetes demand significant healthcare resources. Existing data demonstrate a negative impact on QoL as individual conditions, but there is less evidence relating to the impact of these disease groups in combination. This study therefore explores QoL in patients with AF and diabetes.

This cross-sectional, observational study required participants to complete the short form (SF)-36 survey via an online platform and was offered to people affected by AF alone and people with AF and diabetes in combination. The SF-36 provides a prevalidated tool with eight domains relating to physical and psychological health.

A total of 306 surveys were completed (231 AF group, 75 AF and diabetes group). The mean and standard deviation (SD) were calculated for each QoL domain, after re-coding in accordance with SF-36 guidance. Multi-variate analysis of variance (MANOVA) demonstrated an overall significant difference between the groups when considered jointly across all domains. There were significant differences between AF and AF with diabetes QoL responses in physical functioning, energy fatigue, emotional wellbeing, social functioning and pain. In these domains, the mean was highest in the AF group. There were no significant differences in the role physical, role emotional and general health domains.

In conclusion, this study demonstrates that diabetes and AF has a more detrimental effect on QoL than AF alone, in the majority of domains. Further research into the general AF population and where chronic conditions co-exist is important to comprehend the true impact this disease combination has on QoL.

| Full text

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now